Cognition Therapeutics

Cognition Therapeutics

Cognition Therapeutics is a biotechnology and pharmaceutical company developing therapeutics for Alzheimer’s disease and other neurodegenerative disorders that is headquartered in Pittsburgh, Pennsylvania in 2007 by Gilbert Rishton and Susan Catalano.

Cognition Therapeutics is a biotechnology and pharmaceutical company that was founded by Gilbert Rishton and Susan Catalano in 2007, and is headquartered in Pittsburgh, Pennsylvania.

Cognition Therapeutics engages in drug development and discovery to develop novel approaches to the treatment of central nervous system disorders. The companies treatment approach to central nervous system disorders, such as Alzheimers disease and other neurodegenerative disorders, is to prevent the accumulation of toxic proteins associated with central nervous system disorders through the discovery and application of small molecule drug therapies.

Cognition’s lead candidate product is Elayta, an orally available small molecule was shown in clinical studies to have potential to normalize protein trafficking and lipid metabolism pathways disrupted in Alzheimer’s disease and allow protection and restoration of synapses. As of 2019 three Phase 2 clinical studies testing Elayta were SPARC (Synaptic Protection for Alzheimer’s Restoration of Cognition), SNAP (AβO Displacement from Synapses on Neurons in Alzheimer’s Patients), and SHINE (Synaptic Health and Improvement of Neurological Function with Elayta). These studies were supported by grants (award numbers RF1AG057780, RF1AG057553 and R01AG058660) from the National Institute on Aging of the NIH. Elayta was granted Fast Track designation by the U.S. FDA.

Timeline

September 13, 2013

Cognition Therapeutics raises a $3,000,000 series B round.

July 15, 2009

Cognition Therapeutics raises a $1,210,000 series A round from Innovation Works and Pittsburgh Life Sciences Greenhouse.

2007

Cognition Therapeutics was founded.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
3 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Alexander Craig

Investor

Alicia Syrett

Investor

Anne Estabrook

Investor

David Hunt/Hunt Technology Ventures, L.P.

Investor

Deb Gerardi Kemper

Investor

Elinor MacKinnon

Investor

Gilbert Rishton

Chief Medicinal Chemistry Advisor

Hank Safferstein

Senior Vice President

Hans Hugh Miller

Investor

Jacqueline Dedell

Investor

James M. O’Brien

Chief Financial Officer

Jean Peters

Investor

Jenevra Georgini

Investor

John B Goodrich

Investor

Kat Dave

Investor

Kenneth Moch

President & CEO

Marc Brands

Investor

Marcia Rick Dawood

Investor

Marjorie Kaufman, CFA

Investor

Michael Grundman

Chief Medical Advisor

Robert Windsor

Investor

Squirrel Hill Ventures

Investor

Stephen DiPalma

former Chief Financial Officer

Susan Catalano

Founder & Chief Science Officer

Further reading

Title
Author
Link
Type
Date

Cognition Therapeutics Expands Industry-Leading Expertise in Research and Clinical Use of Biomarkers of Alzheimer's Disease

Cognition Therapeutics, Inc.

Web

Cognition Therapeutics making strides in Alzheimer's research - Ben Franklin Technology Partners of Pennsylvania

Ben Franklin Technology Parters

Web

Cognition Therapeutics Receives $16.6 Million Multiyear NIA Grant for Phase 2 SHINE Study of ElaytaTM in Patients with Mild-to-Moderate Alzheimer's Disease

Cognition Therapeutics, Inc.

Web

Documentaries, videos and podcasts

Title
Date
Link

Dr. Susan Catalano of Cognition Therapeutics | Bootstrapping in America

July 18, 2018

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.